Company news

Dimerix Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Dimerix Quarterly Activities Report and Appendix 4C

October 28, 2026

Dimerix Quarterly Activities Report and Appendix 4C

October 28, 2026

New Data Supports Biological Rationale for DMX-200 in FSGS

October 22, 2026

DMX-200 First 100 Patients Complete Phase 3 Trial Treatment

October 15, 2026

First Patient Reaches Four Years in DMX-200 Clinical Program

October 4, 2026

Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility

September 22, 2026

Dimerix DMX-652 Granted Mexican Composition of Matter Patent

September 13, 2026

S&P DJI Announces September 2026 Quarterly Rebalance

September 4, 2026

Dimerix secures a$34 million non-dilutive facility to fund key clinical milestones

September 3, 2026

Dimerix Secures A$34 Million Non-Dilutive Funding Facility

September 3, 2026

Appendix 4E and 2026 Annual Report

August 26, 2026

Dimerix Receives US$10M Upfront Payment from Everest

August 19, 2026

Dimerix Assumes Sponsorship of US IND for New Asset DMX-652

August 16, 2026

Dimerix Presents at Bioshares Summit 2026

August 5, 2026

US Patent Granted for Dimerix New Asset DMX-652

July 22, 2026

Dimerix expands pipeline with acquisition of Phase 2 ready asset for acute kidney injury

July 17, 2026

Dimerix Expands Pipeline with Acquisition of Phase 2 Asset

July 16, 2026

Dimerix Non-Dilutive Funding Builds Pipeline, Boosts Runway

July 16, 2026

DMX-200 Available To Patients Via Post-Trial Access Pathways

July 8, 2026

Dimerix exclusively licenses DMX-200 in Greater China, South Korea and Southeast Asia to Everest Medicines

June 15, 2026

Dimerix Licenses DMX200 to Everest for China and Asia Region

June 15, 2026

Dimerix Quarterly Activities Report and Appendix 4C

April 29, 2026

Blinded assessment of ACTION3 statistical assumptions complete

April 27, 2026

ACTION3 Statistical Review Complete

April 27, 2026

Dimerix to Conduct Review of ACTION3 Statistical Assumptions

March 15, 2026

Dimerix Phase 3 Trial Last Patient Receives First Dose

March 9, 2026

Appendix 4D and Half Year Financial Report

February 25, 2026

Quarterly Appendix 4C and Activities Report

January 28, 2026

BioMarin to acquire Dimerix US Partner, Amicus Therapeutics

December 21, 2025

DMX-200 ACTION3 Phase 3 trial completes recruitment

December 15, 2025

DMX-200 ACTION3 Phase 3 Trial Completes Recruitment

December 14, 2025

Successful Completion of Planned IDMC Review

November 18, 2025

Successful PARASOL Collaboration Data Analysis Outcome

October 7, 2025

DMX-200 receives Orphan Drug Designation in Japan

September 29, 2025

Appendix 4E and 2025 Annual Report

August 27, 2025

Dimerix receives 1st Development Milestone payment from FUSO

June 29, 2025

ACTION3 Clinical Trial Milestone Recruitment Update

June 12, 2025

1st ACTION3 site in Japan activated and milestone triggered

May 29, 2025

Successful planned IDMC review of ACTION3 trial

May 21, 2025

Dimerix receives initial upfront payment from Amicus

May 5, 2025

Investor Webinar and Presentation

April 30, 2025

Dimerix Licenses DMX-200 in the US

April 30, 2025

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

April 30, 2025

Trading Halt

April 28, 2025

FDA confirms Proteinuria as Primary Endpoint for US approval

April 27, 2025

S&P DJI Announces March 2025 Quarterly Rebalance

March 7, 2025

Dimerix receives initial upfront payment from FUSO

March 3, 2025

Half-Year Financial Report & Appendix 4D - 31 December 2024

February 24, 2025

First Paediatric Patient Recruited for ACTION3

January 15, 2025

Dimerix enters Development and License Agreement for Japan

January 6, 2025

Older news releases →

Decks

The 5 newest of 83 decks. Every deck is listed under its year.